

Advanced breast cancer: diagnosis and management (Partial update)

Review Questions

NICE guideline CG81

Review Questions

February 2026

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.

Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the [Welsh Government](#), [Scottish Government](#), and [Northern Ireland Executive](#). All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2026. All rights reserved. Subject to [Notice of rights](#).

Contents

1	Review Questions.....	5
---	-----------------------	---

1 Review Questions

Review Question 1: What is the clinical and cost effectiveness of a platinum-containing chemotherapy regimen compared to a non-platinum-containing chemotherapy regimen in people with advanced:

- triple negative breast cancer
- breast cancer of any receptor sub-type with germline BRCA mutations?

Review Question 2:

Part 1: What is the clinical and cost effectiveness of FDG PET-CT compared to CT (with or without bone scintigraphy) for diagnosing distant metastases and determining subsequent management in people with suspected advanced breast cancer?

Part 2: In adults with suspected advanced breast cancer, what is the diagnostic accuracy and cost effectiveness of:

- FDG PET-CT
- CT (with or without bone scintigraphy)

for detecting distant metastases?

Review Question 3: What is the clinical and cost effectiveness of FDG PET-CT compared to CT with or without bone scintigraphy for monitoring response to treatment in people who have been or are being treated for advanced breast cancer?